Answers are grounded in this paper and cite their sources.
Most blood-based cancer detection tests are locked at launch, even though the populations, assays and clinical practices around them keep changing. We argue that multi-analyte early-detection models should be adaptive: recalibrated as outcome-linked results accumulate, and governed by versioning, human-gated updates, drift monitoring and documented re-validation. Using pancreatic ductal adenocarcinoma as a case study, we describe how the CLIA framework and FDA Predetermined Change Control Plans can support safe, continuous improvement.
No takes yet. Share an insight, caveat, or question.
Sean McCafferty (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: